[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR9709238A - Uso de Il-12 e alfa-interferon para o tratamento de doenças infecciosas - Google Patents

Uso de Il-12 e alfa-interferon para o tratamento de doenças infecciosas

Info

Publication number
BR9709238A
BR9709238A BR9709238A BR9709238A BR9709238A BR 9709238 A BR9709238 A BR 9709238A BR 9709238 A BR9709238 A BR 9709238A BR 9709238 A BR9709238 A BR 9709238A BR 9709238 A BR9709238 A BR 9709238A
Authority
BR
Brazil
Prior art keywords
interferon
alpha
treatment
infectious diseases
infectious
Prior art date
Application number
BR9709238A
Other languages
English (en)
Inventor
Alber Gottfried
Jacqueline Anne Carr
Frank Albert Mattner
Michael John Mulqueen
Kathrin Palmer
Jane Andre Louise Rogerson
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR9709238A publication Critical patent/BR9709238A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • A61P33/12Schistosomicides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR9709238A 1996-05-13 1997-05-07 Uso de Il-12 e alfa-interferon para o tratamento de doenças infecciosas BR9709238A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9609932.0A GB9609932D0 (en) 1996-05-13 1996-05-13 Use of IL-12 and IFN alpha for the treatment of infectious diseases
PCT/EP1997/002336 WO1997042969A1 (en) 1996-05-13 1997-05-07 USE OF IL-12 AND IFN-α FOR THE TREATMENT OF INFECTIOUS DISEASES

Publications (1)

Publication Number Publication Date
BR9709238A true BR9709238A (pt) 1999-08-10

Family

ID=10793602

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9709238A BR9709238A (pt) 1996-05-13 1997-05-07 Uso de Il-12 e alfa-interferon para o tratamento de doenças infecciosas

Country Status (14)

Country Link
US (1) US5928636A (pt)
EP (1) EP0907373B1 (pt)
JP (1) JP3246918B2 (pt)
CN (1) CN1178694C (pt)
AR (1) AR007051A1 (pt)
AT (1) ATE270556T1 (pt)
BR (1) BR9709238A (pt)
CA (1) CA2253490C (pt)
DE (1) DE69729796T2 (pt)
ES (1) ES2224246T3 (pt)
GB (1) GB9609932D0 (pt)
PT (1) PT907373E (pt)
TR (1) TR199802329T2 (pt)
WO (1) WO1997042969A1 (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012739A1 (en) * 1998-08-26 2000-03-09 Basf Aktiengesellschaft Methods and compositions for expressing heterologous genes in hepatocytes using hepadnaviral vectors
PE20001548A1 (es) * 1999-03-02 2001-01-16 Schering Corp Uso de interferon alfa pegilado para el tratamiento de vih-1
US6635646B1 (en) 1999-05-04 2003-10-21 Schering Corporation Pegylated interferon alfa-CCR5 antagonist combination HIV therapy
HUP0202734A3 (en) * 1999-05-04 2003-11-28 Schering Corp Use of pegylated interfron alfa-ccr5 antagonist combination for hiv therapy
US20020004584A1 (en) * 2000-03-09 2002-01-10 Laughlin Mark A. HIV immune adjuvant therapy
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
AP2006003708A0 (en) 2000-05-26 2006-08-31 Idenix Cayman Ltd Methods and compositions for treating flavivirusesand pestiviruses
WO2002044717A1 (en) * 2000-12-01 2002-06-06 Cornell Research Foundation Animal model for flaviviridae infection
WO2003026589A2 (en) * 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
NZ537662A (en) * 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
RS113904A (en) * 2002-06-28 2007-02-05 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
CN100348607C (zh) 2002-06-28 2007-11-14 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒科病毒感染的2’和3’-核苷前药
ES2624353T3 (es) * 2002-11-15 2017-07-13 Idenix Pharmaceuticals Llc 2'-Metil nucleósidos en combinación con interferón y mutación de Flaviviridae
ES2470771T3 (es) * 2002-12-12 2014-06-24 Idenix Pharmaceuticals, Inc Procedimiento para la producción de nucle�sidos ramificados en 2'
EP1599171A2 (en) * 2003-02-28 2005-11-30 Intermune, Inc. Combination therapy for treating alphavirus infection and liver fibrosis
EP1633766B1 (en) 2003-05-30 2019-03-06 Gilead Pharmasset LLC Modified fluorinated nucleoside analogues
CA2536041A1 (en) * 2003-11-10 2005-05-26 Angiotech International Ag Medical implants and fibrosis-inducing agents
CN1980657A (zh) 2004-05-05 2007-06-13 耶鲁大学 新颖的抗病毒赛菊宁黄质类似物
WO2005123113A2 (en) * 2004-06-14 2005-12-29 Intermune, Inc. Interferon compositions and methods of use thereof
CN101023094B (zh) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
ES2769377T3 (es) * 2004-09-14 2020-06-25 Gilead Pharmasset Llc Intermedios de D-ribonolactona con sustitución de 2-fluoro-2-alquilo
ES2302402B1 (es) * 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
EP1976382B1 (en) * 2005-12-23 2013-04-24 IDENIX Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EA022952B1 (ru) * 2008-07-23 2016-03-31 Тамара Александровна ВИТКАЛОВА Способ лечения вирусных гепатитов b и c
CN102325783A (zh) 2008-12-23 2012-01-18 法莫赛特股份有限公司 嘌呤核苷的合成
SG172361A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Nucleoside analogs
SG172359A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
MX2012011171A (es) 2010-03-31 2013-02-01 Gilead Pharmasset Llc Fosforamidatos de nucleosido.
CN102309758B (zh) * 2010-07-02 2013-02-20 北京凯因科技股份有限公司 一种治疗肠道病毒感染引起的疾病的药物组合物
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
RU2482848C1 (ru) * 2011-12-30 2013-05-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Северо-Западный государственный медицинский университет им. И.И. Мечникова" Министерства здравоохранения и социального развития Российской Федерации Способ лечения больных с лекарственно-устойчивым туберкулезом и вич-инфекцией
CN102512448B (zh) * 2011-12-30 2013-03-27 江苏省疾病预防控制中心 Dc-cik细胞在制备抗hiv感染的药物中的应用
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
KR102239196B1 (ko) 2013-08-27 2021-04-12 길리애드 파마셋 엘엘씨 2종의 항바이러스 화합물의 조합 제제
JP2020527153A (ja) * 2017-07-17 2020-09-03 シュ ド ナント − セントレ ホスピタリエ ユニヴェルシテール ド ナント − 二次疾患の治療における使用のためのインターロイキン12(il12)又はその誘導体
WO2024186735A1 (en) * 2023-03-03 2024-09-12 Memorial Sloan-Kettering Cancer Center Methods and compositions for the treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341567C (en) * 1980-01-08 2008-02-19 Charles Weissmann Dna sequences, recombinant dna molecules and processes for producing human interferon - like polypeptides
CH657141A5 (de) * 1980-07-01 1986-08-15 Hoffmann La Roche Dns-sequenzen, rekombinante expressionsvektoren zur mikrobiellen herstellung von human-leukozyten-interferonen und transformierte mikroorganismen.
DE3574145D1 (en) * 1984-08-27 1989-12-14 Genentech Inc Novel, distinct family of human leukocyte interferons, compositions containing them, methods for their production, and dna and transfected hosts therefor
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
ATE140483T1 (de) * 1988-11-10 1996-08-15 Genetics Inst Natürlicher killerzellen-stimulationsfaktor
EP0433827B1 (en) * 1989-12-22 1998-03-04 F. Hoffmann-La Roche Ag Cytotoxic lymphocyte maturation factor
CA2180193A1 (en) * 1995-06-28 1996-12-29 Edward Baral Enhancing host immunity against viral infections

Also Published As

Publication number Publication date
EP0907373B1 (en) 2004-07-07
PT907373E (pt) 2004-10-29
EP0907373A1 (en) 1999-04-14
WO1997042969A1 (en) 1997-11-20
CA2253490A1 (en) 1997-11-20
DE69729796D1 (de) 2004-08-12
CN1218410A (zh) 1999-06-02
DE69729796T2 (de) 2005-07-14
JP3246918B2 (ja) 2002-01-15
ATE270556T1 (de) 2004-07-15
AR007051A1 (es) 1999-10-13
CN1178694C (zh) 2004-12-08
CA2253490C (en) 2003-02-04
US5928636A (en) 1999-07-27
GB9609932D0 (en) 1996-07-17
TR199802329T2 (xx) 2002-12-23
JP2000504029A (ja) 2000-04-04
ES2224246T3 (es) 2005-03-01

Similar Documents

Publication Publication Date Title
BR9709238A (pt) Uso de Il-12 e alfa-interferon para o tratamento de doenças infecciosas
EE9800382A (et) Lihtherpese viiruse ja teiste nakkushaiguste antimikroobne ravimenetlus
BR9706968A (pt) Uso de antagonistas de alfa-ppar e gama-ppar para o tratamento de sindrome x
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
BR9608758A (pt) Uso de ribavirina e interferom alfa para o tratamento de hepatite c
ATE363904T1 (de) Benzimidazol-2-carbamat zur behandlung viraler infektionen und von krebs
BR9508886A (pt) Compostos e métodos para o tratamento de câncer
BR9307084A (pt) Suporte para cabeça e suporte cirúrgico para cabeça
BR9609532A (pt) Composição antimicrobiana para o tratamento de cabelo processo para o tratamento de caspa e uso da composição
FI953479A0 (fi) 1-aryylipyrimidiinijohdannaiset ja niiden farmaseuttinen käyttö
DE69504408D1 (de) Antibakterielle Keramik und antibakterieller keramischer Filter
DE4480670T1 (de) Wäßrige Dispersionszusammensetzung und diese nutzende Zusammensetzung
DE69302234D1 (de) Menschliches Prohibitin und Prohibitin kodierende DNS
IT1277461B1 (it) Procedimento e dispositivo per il trattamento di materiali
PT928193E (pt) Utilizacao de 1-hidroxi-2-piridonas para o tratamento de infeccoes da pele
DE59707096D1 (de) Haarbehandlungsmittel zur Festigung der Haare
PT983271E (pt) Hemissulfato carbociclico nucleosidico e a sua utilizacao no tratamento de infeccoes virais
DE69830259D1 (de) Gewebeschutzmittel und der Gebrauch desselben
BR9606631A (pt) Preparado para o tratamento e condicionamento do cabelo e seu emprego
FI963263A0 (fi) Bromelaiinin lääkinnällinen käyttö
PT804199E (pt) Uso de penciclovir para o tratamento de nevralgias pos-herpeticas
BR9303545A (pt) Procedimento para o tratamento e conformaçao do cabelo
KR960009975U (ko) 일회용 반창고
DK0907373T3 (da) Anvendelse af synergistiske sammensætninger af IL-12 og IFN-alfa til behandling af infektionssygsomme
BR9404688A (pt) Composiçao de matéria processo para o tratamento de doenças virais e tumorais e uso da composiçao

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09S Decision of refusal: publication cancelled [chapter 9.2.2 patent gazette]

Free format text: ANULADA A PUBLICACAO DE INDEFERIMENTO POR TER SIDO INDEVIDA.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]